Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2022

View Archived Issues

New monoglyceride lipase inhibitors identified at Roche

LG Chem discovers diacylglycerol O-acyltransferase 2 inhibitors

Seoul National University Hospital patents triglyceride-lowering peptides

Friedrich-Alexander-University Erlangen-Nuremberg presents mu-opioid receptor agonists

New USP7 inhibitors identified at Shouyao Holdings

Elicio Therapeutics' TLR9 agonist AMP-CpG induces potent immune and antitumoral effects

PF-07038124: a topical PDE4 inhibitor for atopic dermatitis and plaque psoriasis

LNP formulation development and production service launched by eTheRNA Manufacturing

Artelo collaborates with Trinity College Dublin to better understand FABP inhibition in cancer

Flavonoids as nuclear receptor 4A1 ligands for treating rhabdomyosarcoma

Novel NR4A1 antagonists show antitumor activity in syngeneic mouse model of colon cancer

Gain-of-function study identifies T-cell boosters

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...